Explore the promising data on elinzanetant for managing menopause-related vasomotor symptoms, highlighting its tolerability and minimal side effects.
James Simon, MD, CCD, MSCP, IF, FACOG
Advertisement
Articles by James Simon, MD, CCD, MSCP, IF, FACOG
Advertisement
Latest Updated Articles
New Data Show Elinzanetant Is a Safe, Well-Tolerated Nonhormonal Therapy for Menopausal Vasomotor SymptomsPublished: October 24th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA, ASH Experts Review Newly Approved Therapies in Hemophilia
2
How a New Generation of CAR T-Cell Therapies Could Reduce the Risk of Rejection
3
Pharmacist Strategies for Managing Comorbid Depression and Diabetes
4
A Cup of Coffee or Life-Saving Drugs: Shifting Decision-Making Practices in Health Care
5
